SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services," Sanders said in a statement. (Photo: Gage Skidmore/Flickr/cc)
Sanders: Trump's HHS Pick Proves He Was 'Never Serious' About Taking on Big Pharma
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge."
Nov 13, 2017
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.